Disclaimer免責條款所有討論,當力保持平客觀,唯任何人仕採用時當自行判斷,一切意見,只作一般參考用途,不得視為具法律約束力 之專業意見,網主對任何因使用或不當使用網站提供之內容而引致之有形或無形損失,概不承擔任何義務或責任。詳情免責條款: |
妖魔化疫苗現像-廿一世紀的反智逆流案例 2
Demonization of Vaccine As A Phenomenon of
Anti-Intellectualiam in 21 Century 2
-30/04/2021
正如前文所説,明明白白正式的統計數據放在那裡不看,偏偏有人聽信不可證實的謠言或故意誤導的訊息。不談遠的,自第一輪疫苗接種服務開始 後,政府便啟動疫苗不良反應事件監察系統(COVID-19 Vaccine Adverse Event Online Reporting system- (www.drugoffice.gov.hk/eps/do/en/healthcare_providers/adr_reporting/index.html)), 到下筆為止,本地累積接種人數已過一百萬人,完成接種兩針的人數達69萬。由於早期以長者為主,體質和健康狀態一定不及年青人,但結果並未有確實死亡案例 和接種疫苗有關,不良副作用的數量亦有限,大家可自行訪問上面顯示的政府官方網站。但某些傳媒利用事件並列的方式,成功製造了一定的聯想效應,然後便令謠 言在各社交平台上流傳。
如果説謠言止於智者,那只能嘆息智者原來無法藉教育普及而提升,不少受過高等教育的人士同樣抗拒疫苗。現時香港採用的疫苗,都是在外地被 被廣泛採用了一段時間,而統計數據説明没有明顯副作用或極為輕微,根據指引,孕婦,高血壓達160,嚴重糖尿病、甲狀腺亢奮、心臟病等正服食藥物人士,才 需要咨詢醫生,很多仍能接種。但謠言把很多正常健康生活工作的人也嚇得猶豫起來,如果這些人在反應温和的新冠疫苗下也這樣脆弱,那麽症狀更嚴重的傷風感冒 豈不是非常危險?真的感染新冠便很大可能會致命。如前文所述,新冠感染率達0.155%,風險豈非更高。
從好的方向想,本地人都是富命貴,特别衿貴,所以杞人憂天,況且少逛街購物做次體檢很平常。不過,現實中,本地活在貧窮線下的人口達 149萬或人口21.4%,而且趨勢向上,他們欠缺體檢資源和知識,不少長者仍在工作拼搏,稍為年青没醫療券的,接種疫苗已需要耗掉半天假期,如再做個全 面體檢,金錢時間的消耗不容易,謠言驅使這些生活條件更惡劣也更易被感染的的基層人口抗拒疫苗,對社會有什麽好處?在一些國家中,基層没有醫療保障,交不 起醫保金,一針難求,在新冠下死亡率高企;難得香港的疫苗接種是全民免費,卻有人作妖,阻礙香港早日解除疫情威脅,用意何在?
註1
The Prevention and Control of Disease (Use of Vaccines) Regulation (Cap. 599K) (the Regulation)
註2
https://www.info.gov.hk/gia/general/202102/26/P2021022600625.htm
....Currently, the DH has established a pharmacovigilance system to
receive and assess reports of adverse events following immunisations
(AEFIs) submitted by healthcare professionals (for example, registered
medical practitioners, nurses and pharmacists) and the pharmaceutical
industry, in particular serious AEFIs, and conduct causality
assessments to ascertain whether the adverse events were associated
with the vaccinations.
i) A dedicated COVID-19 Vaccine Adverse Event Online Reporting system
has been set up
(www.drugoffice.gov.hk/eps/do/en/healthcare_providers/adr_reporting/index.html)
to receive AEFI reports of COVID-19 vaccines from healthcare
professionals and the pharmaceutical industry;
(ii) Letters to healthcare professionals and relevant organisations
have been issued to encourage them to report suspected serious or
unexpected AEFIs
(www.drugoffice.gov.hk/eps/upload/eps_news/43289/EN/1/DHPL_Reporting%20of%20Adverse%20Event%20following%20Immunization%20(AEFI)%20of%20COVID-19%20Vaccine.pdf);
and
(iii) For active surveillance, the DH has partnered with the Department
of Pharmacology and Pharmacy of the University of Hong Kong to actively
collect data of potential adverse events of authorised vaccines, in
particular rare or serious adverse events of special interest (AESI)
(e.g. Guillain Barre syndrome, acute disseminated encephalomyelitis)
from public and private healthcare facilities and conduct causality
assessments. At the same time, comprehensive monitoring of all
potential adverse events amongst the different authorised COVID-19
vaccines from selected target groups will also be conducted.
- 完 -